- Home
- ORIS vs RLYB Comparison
ORIS vs RLYB Comparison
Compare ORIS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- RLYB
- Stock Information
- Founded
- ORIS 2014
- RLYB 2018
- Country
- ORIS China
- RLYB United States
- Employees
- ORIS N/A
- RLYB N/A
- Industry
- ORIS Farming/Seeds/Milling
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- RLYB Health Care
- Exchange
- ORIS Nasdaq
- RLYB Nasdaq
- Market Cap
- ORIS 40.5M
- RLYB 42.7M
- IPO Year
- ORIS 2024
- RLYB 2021
- Fundamental
- Price
- ORIS $1.52
- RLYB $0.89
- Analyst Decision
- ORIS
- RLYB Buy
- Analyst Count
- ORIS 0
- RLYB 6
- Target Price
- ORIS N/A
- RLYB $8.10
- AVG Volume (30 Days)
- ORIS 2.2M
- RLYB 94.2K
- Earning Date
- ORIS 02-21-2025
- RLYB 03-11-2025
- Dividend Yield
- ORIS N/A
- RLYB N/A
- EPS Growth
- ORIS N/A
- RLYB N/A
- EPS
- ORIS 0.43
- RLYB N/A
- Revenue
- ORIS $16,745,999.00
- RLYB $598,000.00
- Revenue This Year
- ORIS N/A
- RLYB N/A
- Revenue Next Year
- ORIS N/A
- RLYB N/A
- P/E Ratio
- ORIS $3.70
- RLYB N/A
- Revenue Growth
- ORIS N/A
- RLYB N/A
- 52 Week Low
- ORIS $1.16
- RLYB $0.84
- 52 Week High
- ORIS $56.01
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- RLYB 40.58
- Support Level
- ORIS N/A
- RLYB $0.89
- Resistance Level
- ORIS N/A
- RLYB $0.95
- Average True Range (ATR)
- ORIS 0.00
- RLYB 0.07
- MACD
- ORIS 0.00
- RLYB -0.01
- Stochastic Oscillator
- ORIS 0.00
- RLYB 19.02
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.